Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $4.6B | $4.3B | $4.1B | $3.8B | $3.7B | $3.1B | $2.4B | $2.2B | $1.9B | $1.6B | $1.5B | $1.3B | $1.2B | $872M | $586M | $272M | $174M | $128M | $68M | $65M | $45M |
| Bruttoergebnis | $3.9B | $3.8B | $3.6B | $3.4B | $3.1B | $2.7B | $2.2B | $2.0B | $1.8B | $1.5B | $1.4B | $1.2B | $1.1B | $770M | $508M | $258M | $160M | $119M | $54M | $56M | $38M |
| Bruttomarge % | 84.7% | 88.2% | 89.0% | 88.6% | 85.2% | 85.8% | 93.7% | 94.1% | 93.6% | 93.2% | 92.9% | 92.3% | 90.0% | 88.3% | 86.6% | 94.9% | 92.2% | 92.5% | 79.4% | 86.4% | 84.5% |
| Betriebsergebnis (EBIT) | — | $224M | $717M | $579M | ($66M) | $170M | $378M | $532M | $615M | $529M | $592M | $508M | $196M | $340M | $198M | $128M | $58M | $16M | ($170M) | ($139M) | ($78M) |
| Operative Marge % | — | 5.3% | 17.6% | 15.1% | -1.8% | 5.5% | 16.0% | 24.6% | 32.5% | 32.7% | 39.8% | 38.4% | 16.7% | 39.0% | 33.8% | 46.9% | 33.2% | 12.4% | -252.3% | -212.5% | -174.0% |
| Jahresüberschuss | $940M | ($356M) | $560M | $415M | ($224M) | ($329M) | $239M | $523M | $447M | $488M | $397M | $330M | $58M | $216M | $289M | $125M | $33M | ($7M) | ($184M) | ($139M) | ($59M) |
| Nettomarge % | 20.4% | -8.3% | 13.8% | 10.8% | -6.1% | -10.6% | 10.1% | 24.2% | 23.6% | 30.1% | 26.7% | 24.9% | 5.0% | 24.8% | 49.2% | 45.9% | 18.9% | -5.3% | -273.0% | -212.6% | -132.4% |
| EBITDA | — | $108M | $1.5B | $1.4B | $1.5B | $1.0B | $1.0B | $1.0B | $933M | $779M | $754M | $666M | $584M | $454M | $310M | $134M | $54M | $25M | ($126M) | ($128M) | ($68M) |
| Ergebnis je Aktie (EPS) | $14.63 | $-5.84 | $8.49 | $5.76 | $-3.58 | $-5.51 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 | $3.51 | $4.79 | $2.67 | $0.83 | $-0.23 | $-7.19 | $-10.04 | $-4.41 |
| Ausstehende Aktien (Mio.) | — | 61M | 66M | 72M | 63M | 60M | 57M | 58M | 61M | 61M | 62M | 63M | 63M | 62M | 60M | 47M | 39M | 30M | 26M | 14M | 13M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für JAZZ. /companies/us/JAZZ
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms